Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DxS working on Erbitux companion diagnostic

This article was originally published in The Gray Sheet

Executive Summary

Molecular diagnostics firm DxS will develop a K-RAS gene mutation test for use as a companion diagnostic for the metastatic colorectal cancer drug Erbitux (cetuximab) under a collaboration with the drug's developers, Bristol-Myers Squibb and Eli Lilly/ImClone, announced Sept. 2. If approved by FDA, the DxS TheraScreen test would be used to determine which potential Erbitux patients have K-RAS mutations in codons 12 and 13. The use of monoclonal antibody epidermal growth factor receptor (EGFR) inhibitors like Erbitux is not recommended for the treatment of colorectal cancer with K-RAS mutations in codon 12 or 13, DxS notes. DxS inked a similar deal with Amgen for its colorectal cancer drug Vectibix (panitumumab) last December (1"The Gray Sheet" Dec. 8, 2008)

You may also be interested in...

Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer

An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers

DxS Plans PMA For Companion Test To Amgen Colorectal Cancer Drug

Personalized medicine company DxS is preparing a PMA application for a companion diagnostic to Amgen's colorectal cancer drug Vectibix, supported by clinical utility data from a recent Amgen-sponsored clinical trial, according to DxS CEO Stephen Little

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: landmark results for lecanemab in Alzheimer’s; other Alzheimer’s players rise after the lecanemab results; Leqvio’s importance to Novartis; Pfizer’s secret sauce for digitalization; and Amgen’s clinical trial diversity efforts.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts